Improving erythropoietin-stimulating agent administration in a multihospital system through quality improvement initiatives: A pre-post comparison study

Journal of Patient Safety

Volumn 7, Issue 3, 2011, Pages 127-132

  Selvan, Mano S ^a,b,c   Sittig, Dean F ^b,c   Thomas, Eric J ^b,d   Arnold, Cody C ^b,d   Murphy, Robert E ^a,c   Shabot, M Michael ^a,c  

^a MEMORIAL HERMANN HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UT School of Biomedical Informatics   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

clinical decision support systems; epoetin ; quality assurance; safety

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

AGED; ARTICLE; DECISION SUPPORT SYSTEM; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIHOSPITAL SYSTEM; ORGANIZATION AND MANAGEMENT; RETROSPECTIVE STUDY; TOTAL QUALITY MANAGEMENT;

AGED; AGED, 80 AND OVER; DECISION SUPPORT SYSTEMS, CLINICAL; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MULTI-INSTITUTIONAL SYSTEMS; QUALITY IMPROVEMENT; RETROSPECTIVE STUDIES;

EID: 80052262383     PISSN: 15498417     EISSN: 15498425     Source Type: Journal    
DOI: 10.1097/PTS.0b013e318223cb54     Document Type: Review

References (9)

1. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anemia patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet. 2007;369:381-388. (Pubitemid 46188479)
2. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin α in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol. 2005;23:5960-5972.
3. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98: 708-714. (Pubitemid 43821788)
4. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet. 2009;373: 1532-1542.
5. Bohlius J, Engert A, Schwarzer G. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia. JAMA. 2008;300: 2854-2855; author reply 2855-2857.
6. Seidenfeld J, Piper M, Bohlius J, et al. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Comparative Effectiveness Review No. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026). 2006. Rockville, MD: Agency for Healthcare Research and Quality. Available at: Http://effectivehealthcare.ahrq. gov/repFiles/EPO%20Final.pdf. Accessed February 18, 2011.
7. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin α, epoetin A and darbepoetin β in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11:1-202, iii-iv.
8. Erythropoiesis-stimulating agents: statement by FDA. 2007. Available at: Http://www.fda.gov/NewsEvents/Testimony/ucm110908.htm. Accessed on February 18, 2011.
9. Sittig DF, Singh H. A new socio-technical model for studying health information technology in complex adaptive healthcare systems. Qual Saf Health Care. 2010;19(Suppl 3):i68-i74.